With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

Submitted by admin on October 26, 2020 - 11:15am

Source:

Endpoints

News Tags:

AnaptysBio

GSK

Tesaro

Zejula

Headline:

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

snippet:

AnaptysBio $ANAB CEO Hamza Suria is counting up the money he’s due from GlaxoSmithKline.

GSK’s Hal Barron inherited a partnership with AnaptysBio when he bought out Tesaro and gained the PARP drug Zejula a couple of years ago for $5 billion. And he’s willing to pay for the right to try various checkpoint combination drugs with Zejula now that the PD-1 he also got in the deal is teed up for a likely near-term approval.

Search form

You are here

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy